Thank you all for appearing before the committee today.
I only have five minutes, so I can't ask all of you questions. I'm going to focus on Ms. Zimmerman, Mr. Lemaire, and Mr. Harry, in the first instance.
We've heard time and time again from everybody coming before committee about innovation and commercialization, and really the lack of funding for it. We know that the business expenditure on research and development has gone down considerably in the last six years. We are below average. The average in the OECD countries is 1.6% of GDP. We're at 1%, and that's very disconcerting, almost alarming.
In the agriculture industry, as I understand it, you need to be like Apple is in the tech industry. You have to create what people want and need. You talked about it, whether it's traceability, new products, methods of farming, and any number of other things.
In the “Saint Andrews Statement”, I think a word was mentioned about innovation and commercialization—not very much was given to it—and that is the structure for the moving forward, and the discussions on Growing Forward 2. Can each of you—Mr. Lemaire, then Mr. Harry, and then Ms. Zimmerman—express to me how vital that is and whether you have concerns about the absence of investment in innovation and commercialization?
Mr. Bacon, you can be thinking about the next question, which is in regard to the railway performance review. You said that things have changed in the last two years. I'll tell you, it was pretty bad before. I'd like to know what those changes are, and what more can be done and needs to be done in the rail industry specifically?
Mr. Lemaire.